Cargando…

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer

BACKGROUND: Due to its high expression in prostate cancer, PSMA (prostate-specific membrane antigen) represents an ideal target for both diagnostic imaging and endoradiotherapeutic approaches. Based on a previously published highly specific PSMA ligand ([(68)Ga]DOTA-FFK(Sub-KuE)), we developed a cor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weineisen, Martina, Simecek, Jakub, Schottelius, Margret, Schwaiger, Markus, Wester, Hans-Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452638/ https://www.ncbi.nlm.nih.gov/pubmed/26116124 http://dx.doi.org/10.1186/s13550-014-0063-1

Ejemplares similares

Synthesis and Preclinical Evaluation of (177)Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
por: Wurzer, Alexander, et al.
Publicado: (2022)

Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE
por: Schottelius, Margret, et al.
Publicado: (2015)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity
por: Wirtz, Martina, et al.
Publicado: (2018)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
por: Schottelius, Margret, et al.
Publicado: (2015)

The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

[(64)Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model
por: Poschenrieder, Andreas, et al.
Publicado: (2017)

Synthesis of Symmetrical Tetrameric Conjugates of the Radiolanthanide Chelator DOTPI for Application in Endoradiotherapy by Means of Click Chemistry
por: Wurzer, Alexander, et al.
Publicado: (2018)

Single-Center Comparison of [(64)Cu]-DOTAGA-PSMA and [(18)F]-PSMA PET–CT for Imaging Prostate Cancer
por: Mirzaei, Siroos, et al.
Publicado: (2021)

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
por: Osl, Theresa, et al.
Publicado: (2020)

Synthesis and preclinical evaluation of novel (99m)Tc-labeled PSMA ligands for radioguided surgery of prostate cancer
por: Kunert, Jan-Philip, et al.
Publicado: (2023)

First (18)F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
por: Wester, Hans Jürgen, et al.
Publicado: (2015)

Targeted Endoradiotherapy with Lu(2)O(3)-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2022)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

[(99cm)Tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center
por: Werner, P., et al.
Publicado: (2020)

Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy
por: Melzig, Claudius, et al.
Publicado: (2018)

Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis
por: Pfob, Christian H., et al.
Publicado: (2018)

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †
por: Rangger, Christine, et al.
Publicado: (2020)

A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture
por: Luan, Xiaohui, et al.
Publicado: (2022)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

PSMA Ligand Conjugated PCL-PEG Polymeric Micelles Targeted to Prostate Cancer Cells
por: Jin, Jian, et al.
Publicado: (2014)

Pharmaceuticals—Special Issue on Radiopharmaceutical Chemistry between Imaging and Endoradiotherapy
por: Kopka, Klaus
Publicado: (2014)

Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases
por: Pfannkuchen, Nina, et al.
Publicado: (2017)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [(68)Ga]Ga-OncoFAP-DOTAGA
por: Backhaus, P., et al.
Publicado: (2021)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
por: Csikos, Csaba, et al.
Publicado: (2023)

Preclinical comparison of four [(18)F, (nat)Ga]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics
por: Wurzer, Alexander, et al.
Publicado: (2020)

Validation of [(125)I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo
por: Schottelius, Margret, et al.
Publicado: (2019)

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
por: Begum, Nusrat J., et al.
Publicado: (2019)

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
por: Wang, Hui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k4flrqkvc8lc0c132d5sl7m9r0